
    
      In Part A, participants will be enrolled to receive multiple doses of ARO-AAT or placebo at
      varying dose levels. Once Part A is complete, a single dose level for Part B will be selected
      based on safety and pharmacodynamic parameters from Part A. Patients enrolled into Part A
      will roll over to the Part B dose level or continue to receive placebo.
    
  